Cantor Fitzgerald Analysts Give Bellicum Pharmaceuticals (BLCM) a $10.00 Price Target

Bellicum Pharmaceuticals (NASDAQ:BLCM) has been assigned a $10.00 price objective by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Friday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 49.93% from the stock’s current price.

Several other research firms have also commented on BLCM. BidaskClub upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 4th. ValuEngine upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd. Raymond James Financial restated a “buy” rating on shares of Bellicum Pharmaceuticals in a research report on Tuesday, December 12th. Zacks Investment Research lowered Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, January 12th. Finally, Wells Fargo & Co downgraded Bellicum Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.00 target price for the company. in a research note on Wednesday, January 31st. Two research analysts have rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $16.88.

Shares of Bellicum Pharmaceuticals (BLCM) opened at $6.67 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.08 and a quick ratio of 6.08. Bellicum Pharmaceuticals has a 52-week low of $5.02 and a 52-week high of $15.55. The company has a market capitalization of $221.81, a P/E ratio of -2.23 and a beta of 0.70.

In other news, major shareholder Bros. Advisors Lp Baker sold 880,735 shares of the company’s stock in a transaction that occurred on Friday, January 19th. The stock was sold at an average price of $8.20, for a total transaction of $7,222,027.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Alan A. Musso sold 6,206 shares of the company’s stock in a transaction that occurred on Monday, November 27th. The stock was sold at an average price of $9.89, for a total value of $61,377.34. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,165,145 shares of company stock valued at $9,696,662. Corporate insiders own 18.77% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of BLCM. MYDA Advisors LLC acquired a new position in Bellicum Pharmaceuticals in the 4th quarter valued at $118,000. Voya Investment Management LLC acquired a new position in Bellicum Pharmaceuticals in the 2nd quarter valued at $132,000. LPL Financial LLC acquired a new position in Bellicum Pharmaceuticals in the 4th quarter valued at $140,000. Commonwealth Equity Services Inc acquired a new position in Bellicum Pharmaceuticals in the 3rd quarter valued at $142,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Bellicum Pharmaceuticals in the 3rd quarter valued at $164,000. 56.20% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Cantor Fitzgerald Analysts Give Bellicum Pharmaceuticals (BLCM) a $10.00 Price Target” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://stocknewstimes.com/2018/02/23/cantor-fitzgerald-analysts-give-bellicum-pharmaceuticals-blcm-a-10-00-price-target.html.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Analyst Recommendations for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply